World
CONTACTAbout UsCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2025 Equal Entertainment LLC.
All Rights reserved
All Rights reserved
By continuing to use our site, you agree to our Privacy Policy and Terms of Use.
We need your help
Your support makes The Advocate's original LGBTQ+ reporting possible. Become a member today to help us continue this work.
Your support makes The Advocate's original LGBTQ+ reporting possible. Become a member today to help us continue this work.
International trial of HIV microbicides begins
A large multisite clinical trial designed to examine the safety and preliminary effectiveness of two candidate topical microbicides to prevent HIV infection began last week, according to the National Institute of Allergy and Infectious Diseases, which is coordinating the trial. Researchers hope these experimental topical compounds will help women protect themselves against sexually acquired HIV infections. "The majority of new cases of HIV infection in women result from heterosexual intercourse, but women may not always be able to insist that their male partners use measures to prevent HIV transmission," says NIAID director Anthony S. Fauci in a press statement. "If effective, microbicides would be a valuable woman-controlled means of slowing the pace of the HIV/AIDS epidemic."
The first volunteers were enrolled last week in Durban, South Africa, and at the University of Pennsylvania in Philadelphia. Enrollment will begin shortly in Malawi, Tanzania, Zimbabwe, and Zambia. Approximately 3,220 women will be enrolled in the trial, which is expected to last about 30 months. The microbicides to be tested are PRO 2000 and BufferGel. Produced by Indevus Pharmaceuticals, PRO 2000 has shown activity against HIV and other sexually transmitted diseases in both laboratory and animal testing. It is believed to act by inhibiting the entry of HIV and other pathogens into body cells. BufferGel, a product of ReProtect, boosts the natural acidity of the vagina in the presence of seminal fluid. An acidic environment inactivates HIV as well as other pathogens.
For more information about the clinical trial go online to www.hptn.org/index.htm.
Recommended Stories for You
From our Sponsors
Most Popular
More Videos
0 seconds of 1 minute, 37 secondsVolume 0%
Press shift question mark to access a list of keyboard shortcuts
Keyboard Shortcuts
Shortcuts Open/Close/ or ?
Play/PauseSPACE
Increase Volume↑
Decrease Volume↓
Seek Forward→
Seek Backward←
Captions On/Offc
Fullscreen/Exit Fullscreenf
Mute/Unmutem
Decrease Caption Size-
Increase Caption Size+ or =
Seek %0-9
Next Up
Pride Today | Johnny Sibilly Dishes on His Viral Kissing Video With His Boyfriend: 'Kiss Your Man!'
01:37
Copied
Live
00:00
01:37
01:37
Watch Now: Pride Today
Latest Stories
Trading camo for couture, why I refuse to disappear in Trump’s America
June 13 2025 6:00 AM
Gay congressman confronts Pete Hegseth over Harvey Milk ship, military diversity
June 12 2025 9:15 PM
LGBTQ+ immigrants face 'most immediate risk' of ICE raids in Los Angeles
June 13 2025 3:21 PM
'No Kings' protests: What to know about the June 14 rallies against Trump
June 13 2025 12:48 PM
The road to Obergefell: Looking back on a decade of marriage equality
June 13 2025 9:30 AM
Iowa bans Medicaid from covering gender-affirming care for adults
June 12 2025 5:11 PM
Congress members demand that EEOC address gender identity discrimination
June 13 2025 5:26 PM
California sues Trump admin over threats to trans athletes
June 13 2025 7:00 AM